Asceneuron develops oral therapeutics that target tau pathology to treat neurodegenerative disorders, including Alzheimer’s disease and orphan tauopathies. The company addresses the high unmet medical needs in these conditions by blocking the progression of tau-related neurodegeneration.
Funding
$100M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NHFounders
Product
Problem
Neurodegenerative disorders, including Alzheimer’s disease and orphan tauopathies, present a significant unmet medical need due to the progressive nature of tau-related neurodegeneration. Current treatments do not effectively address the underlying tau pathology that drives disease progression.
Solution
Asceneuron is developing a portfolio of oral therapeutics designed to target and block tau pathology, a key driver of neurodegenerative diseases. By directly addressing the tau pathology, Asceneuron aims to slow or halt the progression of diseases such as Alzheimer's and orphan tauopathies. Their approach focuses on developing orally available drugs, which can offer a more convenient and accessible treatment option for patients. The company's research and development efforts are dedicated to discovering and developing innovative treatments that can improve the lives of individuals affected by these debilitating conditions. Asceneuron's pipeline represents a novel approach to treating neurodegenerative disorders by directly targeting the underlying mechanisms of tau-mediated neurodegeneration.
Target Audience
The primary target audience includes patients suffering from neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease, and orphan tauopathies, as well as healthcare providers specializing in these conditions.
Features
- Development of oral therapeutics targeting tau pathology
- Focus on treating neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, and orphan tauopathies
- Pipeline of therapeutics designed to block the progression of tau-related neurodegeneration